remetinostat (SHP-141) - Medivir
TetraLogic: Clinical Trial Update (TetraLogic) - Jan 21, 2016 - Anticipated final results from P2 trial (NCT02213861) for CTCL in mid-2016 
Anticipated P2 data • Non-Hodgkin's Lymphoma • Oncology
http://ir.tetralogicpharma.com/press-release/tetralogic-pharmaceuticals-announces-data-lead-clinical-programs
 
Jan 21, 2016
 
.